A novel compound against oncogenic Aurora kinase A overcomes imatinib resistance in chronic myeloid leukemia cells

Author：

E-ISSN： 1791-2423|46|6|2488-2496

ISSN： 1019-6439

Source： International Journal of Oncology, Vol.46, Iss.6, 2015-01, pp. : 2488-2496

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

慢性髓细胞白血病对伊马替尼产生耐药性的机制 Imatinib Resistance Mechanism on Chronic Myeloid Leukemia

By 夏君燕朱平

World Journal of Cancer Research, Vol. 02, Iss. 03, 2012-07 ,pp. : 15-19

汉斯出版社

Access to resources Recommend Favorite

Novel Therapeutic Agents Against Cancer Stem Cells of Chronic Myeloid Leukemia

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 10, Iss. 2, 2010-02 ,pp. : 111-115

Bentham Science Publishers

Access to resources Recommend Favorite

Specific immune responses against epitopes derived from Aurora kinase A and B in acute myeloid leukemia

By Schneider Vanessa Egenrieder Stephanie Götz Marlies Herbst Cornelia Greiner Jochen Hofmann Susanne

Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. : 1500-1504

Informa Healthcare

Access to resources Recommend Favorite

Imatinib and chronic myeloid leukemia: close to the bone

By Terpos Evangelos

Leukemia and Lymphoma, Vol. 54, Iss. 8, 2013-08 ,pp. : 1581-1582

Informa Healthcare

Access to resources Recommend Favorite

Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia

By Ni Ling-Na

Medical Oncology, Vol. 28, Iss. 1, 2011-03 ,pp. : 265-269

Humana Press, Inc

Access to resources Recommend Favorite